Tumor-specific allogeneic cells for cancer therapy

Expert Opinion on Biological Therapy

Volumn 11, Issue 12, 2011, Pages 1551-1554

  Marcus, Assaf ^a   Eshhar, Zelig ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

adoptive cell therapy (ACT); allogeneic; cancer; chimeric antigen receptor (CAR); egress; FTY720; graft versus tumor (GvT); graft verus host disease (GvHD); hematopoietic cell therapy (HCT); Her2 neu; host versus graft (HvG); T body; tumor

Indexed keywords

ALLOANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FINGOLIMOD; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ADOPTIVE CELL TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; CANCER THERAPY; CELL MIGRATION; CELL THERAPY; CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CONDITIONING; GENETIC ENGINEERING; HUMAN; IMMUNITY; MELANOMA; NEOPLASM; NEUROBLASTOMA; REVIEW; SAFETY; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; NEOPLASMS; RECEPTORS, ANTIGEN; T-LYMPHOCYTES; TREATMENT OUTCOME;

MURINAE;

EID: 80555156071     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.628934     Document Type: Review

References (21)

1. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308
2. Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 2008;134:2014-24
3. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70
4. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4
5. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T Cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33
6. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-110
7. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008(181):329-42
8. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21:215-23
9. Dazzi F, Goldman JM. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med 1998;49:329-40
10. Zakrzewski JL, Suh D, Markley JC, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 2008;26:453-61
11. Boni A, Muranski P, Cassard L, et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008;112:4746-54
12. Cyster JG. Chemokines, sphingosine-1- phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005;23:127-59
13. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
14. Tedesco-Silva H, Szakaly P, Shoker A, et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007;84:885-92
15. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
16. Taylor PA, Ehrhardt MJ, Lees CJ, et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).Blood 2007;110:3480-2488
17. Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 2011;118:975-83
18. Hawkins RE, Gilham DE, Debets R, et al. Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 2010;21:665-72
19. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-26
20. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009;113:1006-15
21. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247-54